T1	Participants 1150 1189	826 patients were randomized and dosed.
T2	Participants 1251 1302	83.7 and 77.8% of patients receiving MMX mesalamine
T3	Participants 1303 1351	in the PP and intent-to-treat (ITT) populations,
T4	Participants 1416 1426	81.5% (PP)
T5	Participants 1431 1442	76.9% (ITT)
T6	Participants 1718 1755	patients with adverse events was 37.1
T7	Participants 1760 1802	36.0% in patients receiving MMX mesalamine
